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Abstract: Glioblastoma multiforme (GBM) is an aggressive adult brain tumour with poor prognosis.
Roles for peptidylarginine deiminases (PADs) in GBM have recently been highlighted. Here, two
GBM cell lines were treated with PAD2, PAD3 and PAD4 isozyme-specific inhibitors. Effects were
assessed on extracellular vesicle (EV) signatures, including EV-microRNA cargo (miR21, miR126 and
miR210), and on changes in cellular protein expression relevant for mitochondrial housekeeping
(prohibitin (PHB)) and cancer progression (stromal interaction molecule 1 (STIM-1) and moesin),
as well as assessing cell invasion. Overall, GBM cell-line specific differences for the three PAD
isozyme-specific inhibitors were observed on modulation of EV-signatures, PHB, STIM-1 and moesin
protein levels, as well as on cell invasion. The PAD3 inhibitor was most effective in modulating
EVs to anti-oncogenic signatures (reduced miR21 and miR210, and elevated miR126), to reduce cell
invasion and to modulate protein expression of pro-GBM proteins in LN229 cells, while the PAD2 and
PAD4 inhibitors were more effective in LN18 cells. Furthermore, Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways for deiminated proteins relating to cancer, metabolism and inflammation
differed between the two GBM cell lines. Our findings highlight roles for the different PAD isozymes
in the heterogeneity of GBM tumours and the potential for tailored PAD-isozyme specific treatment.
Keywords: peptidylarginine deiminases (PADs); protein deimination; extracellular vesicles (EVs);
glioblastoma multiforme (GBM); prohibitin (PHB); Stromal interaction molecule 1 (STIM-1); moesin;
microRNA (miR21, miR126, miR210); HIF-1
1. Introduction
Peptidylarginine deiminases (PADs) are calcium-dependent enzymes which cause structural
changes in target proteins via post-translational deimination, which affects protein function,
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protein–protein interactions, gene regulation and causes generation of neo-epitopes [1–3]. Protein
deimination can also facilitate protein moonlighting, allowing proteins to exhibit a range of physiological
and pathophysiological functions within one polypeptide chain [4,5]. PADs play important roles in
cancer pathogenesis, including in the central nervous system [6–9]. Glioblastoma multiforme (GBM)
is the most common and aggressive form of primary malignant brain tumour in adults. Standard
treatment consists of surgical resection and radiotherapy in combination with temozolomide (TMZ)
chemotherapy [10,11]. GBM has poor prognosis with only 28.4% of patients surviving one year and
3.4% surviving to year five [12–14]. Brain cancer cells are implicated in manipulating not only the
tumour microenvironment but also systemic immunity to their advantage [15,16].
Extracellular vesicles (EVs) are recognised players in mediating such changes, being lipid
bilayer-enclosed structures, 30–1000 nm in diameter, released from cells and acting as key-mediators for
intra/inter-tumour communication through horizontal transfer of functional proteins and nucleic acids
(mRNA, miRNA, lncRNA, sncRNA) [17–20]. EVs have great potential as diagnostic and prognostic
biomarkers in a range of pathologies, including GBM, and therefore increased understanding of
EV-mediated functions in GBM biology is urgently needed [21,22]. In GBM, EV protein-cargo has for
example been associated with the phenotypic signature of GBM cells [23], while TMZ treatment has
been shown to increase EV release in GBM and to promote more pro-oncogenic EV signatures [24].
Similarly, as in other cancers, GBM cells use EVs for inter-cellular communication in the tumour and to
influence the surrounding microenvironment to promote tumour growth, angiogenesis, metabolism
and invasion [20,25–30]. The regulation of EV biogenesis has therefore received increasing attention in
recent years as an interceptive strategy in cancer, both to sensitize cancer cells to chemotherapy and to
limit tumour growth in vivo [8,9,31–38]. The peptidylarginine deiminase (PAD)-mediated pathway of
EV biogenesis has been highlighted as a novel and significant contributor to EV release in a range of
cancer cells [8,9,33,36], including most recently in GBM by our group [9]. We previously showed that
pan-PAD inhibition, using Cl-amidine, significantly modulated EV signatures, both with respect to
EV numbers released, as well as by changing EV-related microRNA cargo to a more anti-oncogenic
signature [9]. As Cl-amdine showed different effects on LN18 and LN229 GBM cells and due to the
fact that it is a pan-PAD inhibitor with inhibitory effects on PAD2, PAD3 and PAD4 isozymes [39],
further studies on assessing PAD2, PAD3 and PAD4 isozyme-specific inhibitors in these two GBM cell
lines are warranted. Novel interventions for targeted EV regulation and inhibition may be of particular
importance in GBM treatment, considering recent reports on TMZ-mediated increase in EV release and
modulated EV cargos dedicated to cell adhesion processes therefore possibly increasing pro-tumoral
communication by standard TMZ treatment [24].
Besides effects on EV release, PADs are well known for their contribution to a range of pathologies,
including cancers, by converting arginines into citrulline, causing post-translational deimination and
changes in target protein tertiary structure and function [1–3,8,40]. PADs are gaining increased attention
in the context of GBM research. Previous studies have established that grade IV GBM patient samples
show an increase in cytoplasmic and nuclear deiminated proteins, albeit not identifying specific protein
candidates [7]. A recent study by our group established that the pan-PAD inhibitor Cl-amidine reduced
deimination of the mitochondrial house-keeping protein prohibitin (PHB) and deimination of histone
H3, as well as identifying a range of protein candidates that are deiminated in LN18 and LN229 cells
under normal growth conditions [9]. This included prohibitin (PHB), a multifaceted protein with
key roles in mitochondrial housekeeping and tumorigenesis [41–44]; Stromal interaction molecule
1 (STIM-1) which is a membrane ER-resident protein with important roles in calcium-homeostasis
and cancer invasion [45–47]; and moesin, a critical factor for cell migration, filopodia formation [48]
and associated with more aggressive forms of GBM [49,50]. The assessment of proteins involved in
mitochondrial function, cancer progression and invasion is of considerable relevance both with respect
to PAD-inhibitor mediated changes in total protein levels and with respect to their post-translational
deimination, as this may affect protein structure, function and protein–protein interactions [1,40].
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As five isozyme-specific PADs are known in mammals [1], which display tissue specific expression
and different preferences for target proteins, the difference in prominence of the main three isozymes
related to cancer and the CNS (PAD2,3 and 4) is of additional interest for isozyme-specific targeting
relating to cancer types and cancer sub-types, including heterogeneous cancers like GBM. Indeed,
in LN18 and LN229 GBM cell lines these three PAD isozymes have been found to be differently
expressed [9] (Supplementary Figure S1A). An increase in PAD4 staining has been reported in
undescribed astrocytomas [51], while PAD2 and PAD3 upregulation via cAMP-PKA signalling has
been shown in U251MG astrocytoma cells [52]. This indicates some differences in PAD isozyme
expression in different glioma and astrocytoma cells. In addition, PAD-upregulation was shown in a
study assessing response to hypoxia in malignant gliomas [53].
Hypoxia related pathways may be of considerable relevance due to the hypoxic core of a tumour
mass, which also contains the therapy resistant glioma stem-like cells, a well-recognized problem in
the standard treatment of GBM tumours [10,11]. PAD activation has indeed been linked to hypoxia
in the CNS [53–55] and deiminated KEGG (Kyoto Encyclopedia of Genes and Genomes) protein
pathways for HIF-1 regulation have been identified to be enriched in animal models of hypoxia- and
cancer-resistance [56,57]. PADs also modulate neuronal stem cell growth and death [58], which is of
importance considering that GBM tumour invasion, progression and chemo-resistance of recurrent
GBM are partly linked to stem-ness [59,60]. Therefore, effects of PAD inhibitors on PAD mediated
pathways including EV-mediated export of a range of cancer and hypoxia related microRNAs are
also of considerable interest. As we have previously shown pan-PAD inhibition to be effective for
regulating EV release and two key microRNAs (miR21 and miR126) in GBM, we furthermore set
out to assess the effects of PAD isozyme-specific inhibitors on these two miRs, as well as on the
hypoxia-related miR210, which is related to more aggressive forms and poor prognosis in GBM [61–63].
Effects of the PAD-isozyme specific inhibitors on the invasion ability of GBM cells was also assessed,
revealing isozyme-specific differences in the two different GBM cell lines, which also related to the
effects observed on EV release inhibition. Furthermore, the PAD2, 3 and 4 isozyme-specific inhibitors
differentially reduced total protein levels of PHB, moesin and STIM-1, showing overall an anti-oncogenic
regulation of these 3 proteins following PAD-inhibitor treatment. In summary, our findings indicate
PAD isozyme-specific regulation in the pro-oncogenic communication in GBM and highlight the
potential of using PAD-isozyme specific inhibition for tailored treatment of GBM subtypes.
2. Results
2.1. PAD Isozyme-Specific Inhibitors Differently Modulate EV Release in LN18 and LN229 GBM Cells
Following 1 h Treatment
Both LN18 and LN229 cells showed significant changes in EV release following 1 h PAD
isozyme-specific inhibitor treatment, and this varied between the two cell lines (Figure 1). Both PAD2
and PAD4 inhibitors showed stronger effects on reducing EV release in LN18 cells (50%), although
not reaching statistical significance (Figure 1A). In the LN229 cells on the contrary, both PAD2 and
PAD4 inhibitor treatment resulted in some increased EV release, although not statistically significant
(Figure 1B). After 1 h treatment with the PAD3 inhibitor, a significant reduction in numbers of EVs
released was observed in the LN229 cells only (5-fold, p = 0.0334), while no significant change was
observed in the LN18 cells.
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Figure 1. Peptidylarginine deiminase (PAD)2, PAD3 and PAD4 isozyme-specific inhibitor treatment 
shows glioblastoma multiforme (GBM) cancer cell line specific regulation of extracellular vesicle (EV) 
release. (A) Effects of PAD2 and PAD4 inhibitors on EV release in LN18 cells. (B) Effects of PAD2 and 
PAD4 inhibitors on EV release in LN229 cells. (C) Effects of PAD3 inhibitor on EV release in LN18 
cells. (D) Effects of PAD3 inhibitor on EV release in LN229. (D). For each set of histograms, 
respectively, the PAD isozyme-specific inhibitor-treated and control-treated cells were run under the 
same experimental conditions. Exact p-values are indicated (* indicates significant differences with p 
< 0.05; n = 3 biological replicates for all). 
Figure 2 furthermore shows representative nanoparticle tracking analysis (NTA) profiles for EV 
size distribution of LN18 and LN229 control and PAD isozyme-specific treated GBM cells (Figure 
2A–H), alongside characterisation of EVs by western blotting using the EV-specific markers CD63 
and Flot-1; the absence of β-actin in EVs was assessed to rule out cell-contamination (Figure 2I). 
Typical morphology of EVs was verified by TEM (Figure 2J). 
Figure 1. Peptidylarginine deiminase (PAD)2, PAD3 and PAD4 isozyme-specific inhibitor treatment
shows glioblastoma multiforme (GBM) cancer cell line specific regulation of extracellular vesicle (EV)
release. (A) Effects of PAD2 and PAD4 inhibitors on EV release in LN18 cells. (B) Effects of PAD2 and
PAD4 inhibitors on EV release in LN229 cells. (C) Effects of PAD3 inhibitor on EV release in LN18 cells.
(D) Effects of PAD3 inhibitor on EV release in LN229. (D). For each set of histograms, respectively, the
PAD isozyme-specific inhibitor-treated and control-treated cells were run under the same experimental
conditions. Exact p-values are indicated (* indicates significant differences with p < 0.05; n = 3 biological
replicates for all).
Figure 2 furthermore shows representative nanoparticle tracking analysis (NTA) profiles for EV
size distribution of LN18 and LN229 control and PAD isozyme-specific treated GBM cells (Figure 2A–H),
alongside characterisation of EVs by western blotting using the EV-specific markers CD63 and Flot-1; the
absence of β-actin in EVs was assessed to rule out cell-contamination (Figure 2I). Typical morphology
of EVs was verified by TEM (Figure 2J).
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Figure 2. NTA size distribution profiles of EVs released from LN18 and LN229 cells following PAD 
isozyme-specific inhibitor treatment for 1 h and EV characterisation. Representative NTA profiles of 
LN18 cells following 1 h PAD inhibitor treatment (A–D): (A) Control DMSO treated cells; (B) PAD2 
inhibitor treated cells; (C) PAD3 inhibitor treated cells; (D) PAD4 inhibitor treated cells. 
Representative NTA profiles of LN229 cells following 1 h PAD inhibitor treatment (E–H): (E) control 
DMSO treated cells; (F) PAD2 inhibitor treated cells; (G) PAD3 inhibitor treated cells; (H) PAD4 
inhibitor treated cells. (I) Western blotting analysis (WB) showing that EVs isolated from LN18 and 
LN229 cells are positive for the EV specific markers CD63 and Flot-1; β-actin is absent from the EVs 
but present in the cells. (J) Transmission electron microscopy (TEM) images showing characteristic 
EV morphology for EVs isolated from both cell lines; the scale bar indicates 50 µm. In the NTA curves 
the black line represents the mean of the 5 repetitive readings per individual sample and the red line 
represents standard error (+/−) between those same 5 readings per sample. Each treatment group was 
measured in 3 biological replicates. 
EV modal size was overall not affected by any of the PAD inhibitors following 1 h treatment 
(Figure 3A–B), except for some increase observed in EV modal size (from 125 nm to 175 nm) following 
1 h treatment with the PAD2 inhibitor in LN18 cells (p = 0.0022) (Figure 3A). 
Figure 2. NTA size distribution profiles of EVs released from LN18 and LN229 cells following PAD
isozyme-sp cific inhibitor treatment for 1 h and racterisation. Representative NTA profiles of
LN18 cells fo lowing 1 h PAD inhib tor treat e ): (A) Control DMSO tr ated cells; (B) PAD2
inhibitor treated cells; (C) PAD3 inhibitor treated cells; (D) PAD4 inhibitor treated cells. R presentative
NTA profiles of LN229 cells following 1 h PAD inhibitor treatment (E–H): (E) control DMSO treated
cells; (F) PAD2 inhibitor treated cells; (G) PAD3 inhibitor treated cells; (H) PAD4 inhibitor treated
cells. (I) Western blotting analysis (WB) showing that EVs isolated from LN18 and LN229 cells are
positive for the EV specific markers CD63 and Flot-1; β-actin is absent from the EVs but present in
the cells. (J) Transmission electron microscopy (TEM) images showing characteristic EV morphology
for EVs isolated from both cell lines; the scale bar indicates 50 µm. In the NTA curves the black line
represents the mean of the 5 repetitive readings per individual sample and the red line represents
standard error (+/−) between those same 5 readings per sample. Each treatment group was measured
in 3 biological replicates.
EV modal siz was verall not aff cted by a y of the PAD inhibitors following 1 h treatment
(Figure 3A,B), xcept for some increase observed in EV modal size (f om 125 nm to 175 nm) following
1 h treatment with the PAD2 inhibitor in LN18 cells (p = 0.0022) (Figure 3A).
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Figure 3. Effects of PAD2, PAD3 and PAD4 isozyme-specific inhibitor treatment on EV modal size in 
GBM cells, following 1 h treatment. (A) Modal size of EVs released from LN18 cells and LN229 cells, 
respectively, following 1 h PAD2 and PAD4 inhibitor treatment. (B) Modal size of EVs released from 
LN18 cells and LN229 cells, respectively, following 1 h PAD3 inhibitor treatment. Exact p-values are 
indicated, error bars show SD (* indicates significant differences with p < 0.05; ns = non-significant 
change; n = 3 biological replicates for all).  
2.2. MicroRNA EV-cargo is Differently Modulated in Response to 1 h PAD Isozyme-Specific Inhibitor 
Treatment in LN18 and LN229 GBM Cells 
When assessing EV cargo for pro-cancerous, GBM and hypoxia related microRNAs (miR21, 
miR126, miR210), respectively, some significant expression changes were observed, specific to the 
two cell lines and in response to the different PAD inhibitors (Figure 4). In LN18 cells, PAD3 inhibitor 
had no significant effects while both PAD2 and PAD4 inhibitors significantly changed EV miR cargo 
as follows: pro-cancerous miR21 was significantly reduced by PAD2 and PAD4 inhibitors in LN18 
cells by 1055-fold and 131-fold, respectively (Figure 4A); the GBM protective microRNA marker 
miR126 was significantly increased by 3.8-fold and 3.9–fold following PAD2 and PAD4 inhibitor 
treatment, respectively (Figure 4B); and the hypoxia related miR210 was significantly reduced by 9.8-
fold and 10.6-fold in LN18 cell-derived EVs following PAD2 and PAD4 inhibitor treatment, 
respectively (Figure 4C). Overall, PAD3 inhibitor was more effective in the LN229 cells and 
significantly reduced miR21 by 535-fold (Figure 4D); significantly increased miR126 by 2.4-fold 
(Figure 4E); and significantly reduced miR210 by 11.4-fold in LN229 cell-derived EVs (Figure 4F). In 
LN229 cells, both PAD2 and PAD4 inhibitor also had some significant anti-oncogenic effect by 
reducing miR21 by 4.6 and 3.4-fold, respectively (Figure 4D), but did neither up-regulate miR126 
(protective in GBM) nor have significant effects on miR210 in cell-derived EVs (Figure 4F). 
Figure 3. Effects of PAD2, PAD3 and PAD4 isozyme-specific inhibitor treatment on EV modal size in
GBM cells, following 1 h treatment. (A) Modal size of EVs released from LN18 cells and LN229 cells,
respectively, following 1 h PAD2 and PAD4 inhibitor treatment. (B) Modal size of EVs released from
LN18 cells and LN229 cells, respectively, following 1 h PAD3 inhibitor treatment. Exact p-values are
indicated, error bars show SD (* indicates significant differences with p < 0.05; ns = non-significant
change; n = 3 biological replicates for all).
2.2. MicroRNA EV-cargo is Differently Modulated in Response to 1 h PAD Isozyme-Specific Inhibitor
Treatment in LN18 and LN229 GBM Cells
When assessing EV cargo for pro-cancerous, GBM and hypoxia related microRNAs (miR21,
miR126, miR210), respectively, some significant expression changes were observed, specific to the two
cell lines and in response to the different PAD inhibitors (Figure 4). In LN18 cells, PAD3 inhibitor had
no significant effects while both PAD2 and PAD4 inhibitors significantly changed EV miR cargo as
follows: pro-cancerous miR21 was significantly reduced by PAD2 and PAD4 inhibitors in LN18 cells
by 1055-fold and 131-fold, respectively (Figure 4A); the GBM protective microRNA marker miR126
was significantly increased by 3.8-fold and 3.9–fold following PAD2 and PAD4 inhibitor treatment,
respectively (Figure 4B); and the hypoxia related miR210 was significantly reduced by 9.8-fold
and 10.6-fold in LN18 cell-derived EVs following PAD2 and PAD4 inhibitor treatment, respectively
(Figure 4C). Overall, PAD3 inhibitor was more effective in the LN229 cells and significantly reduced
miR21 by 535-fold (Figure 4D); significantly increased miR126 by 2.4-fold (Figure 4E); and significantly
reduced miR210 by 11.4-fold in LN229 cell-derived EVs (Figure 4F). In LN229 cells, both PAD2 and
PAD4 inhibitor also had some significant anti-oncogenic effect by reducing miR21 by 4.6 and 3.4-fold,
respectively (Figure 4D), but did neither up-regulate miR126 (protective in GBM) nor have significant
effects on miR210 in cell-derived EVs (Figure 4F).
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Figure 4. PAD isozyme-specific inhibitor mediated effects on EV microRNA cargo is GBM cell line 
specific. LN18 cell-derived EVs following 1 h PAD inhibitor treatment are shown in A–C: (A) PAD2, 
3, and 4 isozyme-specific inhibitor-mediated effects on the pro-oncogenic miR21 in EVs derived from 
LN18 cells. (B) PAD2, 3, and 4 isozyme-specific inhibitor mediated effects on the anti-oncogenic 
miR126 in EVs derived from LN18 cells. (C) PAD2, 3, and 4 isozyme-specific inhibitor mediated effects 
on the hypoxia-related and pro-oncogenic miR210 in LN18 cells. LN229 cell-derived EVs following 1 
h PAD inhibitor treatment are shown in D–F: (D) PAD2, 3, and 4 isozyme-specific inhibitor-mediated 
effects on the pro-oncogenic miR21 in EVs derived from LN229 cells. (E) PAD2, 3, and 4 isozyme-
specific inhibitor mediated effects on the anti-oncogenic miR126 in EVs derived from LN229 cells. (F) 
PAD2, 3, and 4 isozyme-specific inhibitor mediated effects on the hypoxia-related and pro-oncogenic 
miR210 in LN229 cells. Results are represented as relative miR expression compared to the internal 
control miRs (2Λ(−DDCT)) and normalised to expression in control-treated cells; exact p-values are 
indicated, error bars show SD (*indicates significant differences with p < 0.05; n = 3 biological and 3 
technical replicates for all). 
2.3. PAD Isozyme-Specific Inhibitors Affect PHB, STIM-1 and Moesin Protein Expression Differently in 
LN18 and LN229 GBM Cells Following 1 h Treatment 
Following 1 h treatment with PAD2, PAD3, and PAD4 isozyme-specific inhibitors, respectively, 
the protein levels of PHB, STIM-1 and moesin were assessed by western blotting (Figure 5). The levels 
of PHB were somewhat reduced in LN18 cells both by PAD2 inhibitor (7% to 66%) and PAD4 
inhibitor (1% to 49%), although not reaching statistical significance (Figure 5A); a similar pattern was 
seen in LN229 cells, with some reduction for PAD2 (7% to 21%) or PAD4 (19% to 80%) inhibitor 
(Figure 5A), but not reaching statistical significance. For effects on STIM-1 protein levels, both cell 
lines showed some reduction in this invasion protein following PAD2 and PAD4 inhibitor treatment. 
In LN18 cells, a 15% to 90% reduction (albeit non-significant) in STIM-1 was observed following 
PAD2 inhibition, while following PAD4 inhibition a significant (p = 0.0374) 33% to 90% reduction of 
STIM-1 protein levels was observed (Figure 5B). For LN229 cells, a significant (p = 0.0254) 29% to 34% 
reduction was seen in STIM-1 protein levels following PAD2 inhibition, while PAD4 inhibitor 
treatment resulted in 17% to 39% reduction in STIM-1 protein levels, almost reaching significance (p 
= 0.0571). For changes in moesin protein levels, neither PAD2 nor PAD4 inhibitor resulted in 
significant changes in moesin protein levels in LN18 cells, while in LN229 cells, moesin protein levels 
were significantly (p = 0.0163) reduced by 39% to 49% following PAD2 inhibitor treatment and by 
13% to 27% (but non-significant) following PAD4 inhibitor treatment (Figure 5C). 
Figure 4. PAD isozyme-specific inhibitor mediated effects on EV microRNA cargo is GBM cell line
specific. LN18 cell-derived EVs following 1 h PAD inhibitor treatment are shown in A–C: (A) PAD2, 3,
and 4 isozyme-specific inhibitor-mediated effects on the pro-oncogenic miR21 in EVs derived from
LN18 cells. (B) PAD2, 3, and 4 isozyme-specific inhibitor mediated effects on the anti-oncogenic miR126
in EVs derived from LN18 cells. (C) PAD2, 3, and 4 isozyme-specific inhibitor mediated effects on the
hypoxia-related and pro-oncogenic miR210 in LN18 cells. LN229 cell-derived EVs following 1 h PAD
inhibitor treatment are shown in D–F: (D) PAD2, 3, and 4 isozyme-specific inhibitor-mediated effects
on the pro-oncogenic miR21 in EVs derived from LN229 cells. (E) PAD2, 3, and 4 isozyme-specific
inhibitor mediated effects on the anti-oncogenic miR126 in EVs derived from LN229 cells. (F) PAD2, 3,
and 4 isozyme-specific inhibitor mediated effects on the hypoxia-related and pro-oncogenic miR210
in LN229 cells. Results are represented as relative miR expression compared to the internal control
miRs (2Λ(−DDCT)) and normalised to expression in control-treated cells; exact p-values are indicated,
error bars show SD (*indicates significant differences with p < 0.05; n = 3 biological and 3 technical
replicates for all).
2.3. PAD Isozyme-Specific Inhibitors Affect PHB, STIM-1 and Moesin Protein Expression Differently in LN18
and LN229 GBM Cells Following 1 h Treatment
Following 1 h treatment with PAD2, PAD3, and PAD4 isozyme-specific inhibitors, respectively,
the protein levels of PHB, STIM-1 and moesin were assessed by western blotti g (Figure 5). The levels
of PHB were somewhat reduced in LN18 cells both by PAD2 inhibitor (7% to 66%) and PAD4 inhibitor
(1% to 49%), althoug not reaching statistical significance (Figure 5A); a similar pattern was seen in
LN229 cells, with some reduction for PAD2 (7% to 21%) or PAD4 (19% to 80%) inhibitor (Figure 5A),
but not reaching statistical significance. For effects on STIM-1 protein levels, both cell lines showed
some reduction in this invasion protein following PAD2 and PAD4 inhibitor treatment. In LN18 cells,
a 15% to 90% reduction (albeit non-significant) in STIM-1 was observe followi g PAD2 inhibition,
while following PAD4 inhibition a significant (p = 0.0374) 33% to 90% reduction of STIM-1 protein
levels was observed (Figure 5B). For LN229 cells, a significant (p = 0.0254) 29% to 34% reduction was
seen in STIM-1 protein levels followin PAD2 inhibition, while PAD4 inhibitor treatment resulted in
17% to 39% reduction in STIM-1 r tei le els, alm st reaching sig ificance (p = 0.0571). For changes
in mo sin protein levels, neither PAD2 nor PAD4 inhibitor resulted in signific nt chan es in moesin
protein levels in LN18 cells, while in LN229 cells, mo sin protein levels were sig ificantly (p = 0.0163)
reduced by 39% to 49% following PAD2 inhibitor treatment and by 13% to 27% (but non-sig ificant)
following PAD4 inhibitor treatment (Figure 5C).
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Figure 5. PAD2 and PAD4 isozyme-specific inhibitor 1 h treatment affects prohibitin (PHB), stromal 
interaction molecule 1 (STIM-1) and moesin protein levels in LN18 and LN229 GBM cell lines. (A) 
PHB protein levels in LN18 and LN229 cells, respectively, following 1 h treatment with the PAD2 and 
PAD4 inhibitors, compared to control-treated cells. (B) STIM-1 protein levels in LN18 and LN229 cells 
respectively, following 1 h treatment with the PAD2 and PAD4 inhibitors, compared to control-
treated cells. (C) Moesin protein levels in LN18 and LN229 cells, respectively, following 1 h treatment 
with the PAD2 and PAD4 inhibitors, compared to control-treated cells. Representative blots are 
shown; the density ratios of the various proteins analysed and actin are presented as normalised 
quantified data (mean ±S.D.) for treatment with the PAD2 and PAD4 specific inhibitors, compared to 
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cells by 27% to 38% (p = 0.0231), and up to 45% in LN229 cells, albeit non-significantly, following 1 h 
treatment (Figure 6A). PAD3 inhibitor did not significantly change STIM-1 protein levels in LN18 
cells but resulted in significantly reduced STIM-1 protein levels in LN229 cells (26% to 53%; p = 0.0110) 
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Figure 5. PAD2 and PAD4 isozyme-specific inhibitor 1 h treatment affects prohibitin (PHB),
stromal interaction molecule 1 (STIM-1) and moesin protein levels in LN18 and LN229 GBM cell
lines. (A) PHB protein levels in LN18 and LN229 cells, respectively, following 1 h treatment with the
PAD2 and PAD4 inhibitors, compared to control-treated cells. (B) STIM-1 protein levels in LN18 and
LN229 cells respectively, following 1 h treatment with the PAD2 and PAD4 inhibitors, compared to
control-treated cells. (C) Moesin protein levels in LN18 and LN229 cells, respectively, following 1 h
treatment with the PAD2 and PAD4 inhibitors, compared to control-treated cells. Representative blots
are shown; the density ratios of the various proteins analysed and actin are presented as normalised
quantified data (mean ±S.D.) for treatment with the PAD2 and PAD4 specific inhibitors, compared to
DMSO treated controls. The corresponding molecular weight size standard is indicated in kilodaltons
(kDa) on each blot. Exact p-values are indicated, error bars show SD (* indicates significant differences
with p < 0.05; n = 3 biological replicates for all).
Following PAD3 inhibitor treatment, PHB protein levels were significantly reduced in LN18 cells
by 27% to 38% (p = 0.0231), and up to 45% in LN229 cells, albeit non-significantly, following 1 h
treatment (Figure 6A). PAD3 inhibitor did not significantly change STIM-1 protein levels in LN18 cells
but resulted in significantly reduced STIM-1 protein levels in LN229 cells (26% to 53%; p = 0.0110)
(Figure 6B). Moesin protein levels were not significantly affected by PAD3 inhibitor either in LN18
or LN229 cells, although a 1% to 68% (but non-significant) reduction was observed in LN229 cells
(Figure 6C).
Besides assessing a ranging effect of the three isozyme-specific inhibitors on changes of total
protein levels of PHB, moesin and STIM-1, all three proteins were verified to be post-translationally
deiminated as assessed by blotting the F95 protein eluates from both cell lines with the PHB, moesin and
STIM-1 antibodies (Supplementary Figure S1B). Furthermore, FoldIndex© analysis revealed a number
of disordered regions in moesin and STIM-1 (Supplementary Table S1).
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2.4. PAD Isozyme-Specific Inhibitors Differently Affect Invasion in LN18 and LN229 GBM Cells
The invasiveness of LN18 LN229 cells was studied in Boyden chambers with Matrigel. LN18
cells demonstrated noticeable invasion over 16 h (Fig re 7A, A.1), while inva iveness of LN229 c lls
was far lower compared to that observed for LN18 cells. Incubation for 16 h with PAD2 and PAD4
i hibitors resulte in a significant suppression of invasiveness in LN18 cells by 39.3% (p ≤ 0.0001) and
23.2% (p = 0.0020) respectively, while less effect was observed following treatment with the PAD3
inhibitor (9.1%, p = 0.0215) (Figure 7A, A.1; n = 3). Cellular invasion of LN229 cells was overall lower
than for LN18 cells (Figure 7B, control panel), and was significantly suppressed only by the PAD3
inhibitor (16.5%, p = 0.0019) (Figure 7B, B.1; n = 3), while neither PAD2 nor PAD4 inhibitors showed
any significant effect on invasion in LN229 cells (0.4% and 1.25%, respectively; ns; n = 3) (Figure 7B,
B.1). There was no significant change in cell proliferation over the 16 h incubation time with the PAD
inhibitors for either cell line, compared to control treated cells (Figure 8A,B; n = 3).
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Figure 8. Cell proliferation assay for PAD isozyme-specific inhibitors in LN18 and LN229 GBM
cells. (A). Representative images of LN18 and LN229 cells following 16 h treatment with the three
PAD isozyme-specific inhibitors, compared to control (DMSO)-treated cells. (B) (imaged using a 10×
objective). Chresyl violet assay revealed no significant effects (ns) of any of the three inhibitors on cell
proliferation, following 16 h incubation, compared to control (DMSO)-treated cells (n = 3 biological and
3 technical replicates for all).
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2.5. Deiminated Protein Targets and KEGG Networks Enriched in Deiminated Proteins Differ in LN18 and
LN229 GBM Cells under Standard Culture Conditions
STRING analysis revealed some common deiminated KEGG pathways (glycolysis/
gluconeogenesis, ribosome, splicosome, protein processing in ER, carbon metabolism, oestrogen
signalling pathway, biosynthesis of amino acids, arrhythmogenic right ventricular cardiomyopathy,
antigen processing and presentation, Huntington’s disease, pathogenic Escherichia. coli (E. coli) infection)
in both GBM cell lines, while several pathways were enriched for deiminated proteins in LN18 cells only
(gap junction, aminoacyl-tRNA biosynthesis, pentose phosphate pathway; phagosome, necroptosis,
Epstein–Barr virus infection, legionellosis, salmonella infection, mRNA surveillance pathway, longevity
regulating pathway, central carbon metabolism in cancer, HIF-1 signalling pathway, thyroid hormone
synthesis) or in LN229 cells only (pyruvate metabolism, IL-17 signalling pathway). Overall, more
protein hits were identified as deiminated in LN18 cells (417 protein hits; Supplementary Table S2)
compared to in LN229 cells (300 hits; Supplementary Table S3). KEGG pathways for deiminated
proteins identified in both cell lines are presented in Supplementary Figures S3 and S4 for LN18
and LN229 cells, respectively (see also Supplementary Tables S2 and S3 for full LC-MS/MS data
analysis of all protein hits). The Venn diagram in Figure 9 summarises common and distinct KEGG
pathways enriched in deiminated proteins in LN18 and LN229 cells under normal culture conditions
(see Supplementary Figures S3 and S4 for protein–protein interaction networks showing all identified
KEGG pathways enriched in deiminated proteins).
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(LN18 and LN229), under standard culture conditions. For detailed network analysis highlighting the
different KEG pathways in both cell lines see Sup lementary Figures S3 and S4.
3. Discussion
Regulation of EV release is critical for cellular communication and modulation of the
microenvironment in cancer progression and metastasis and recognised to be of increasing importance
in GBM [21,22]. GBM-derived EVs have furthermore been shown to induce tumour-promoting
transformation of subventricular zone resident neural stem cells, possibly contributing to GBM
recurrence [64]. Differences in EV release profiles between GBM cell lines, including EV sub-populations
and during normal growth conditions, have previously been reported by us and others [9,38,65].
Several studies have assessed various types of EV cargo in GBM, including protein and genetic
material [9,20,38,66–68]. Due to a range of pro-oncogenic cargo components transported by GBM cells
for intra-tumour communication and the penumbra, including evidence for increased pro-oncogenic
EV-release in response to standard chemotherapeutic treatment with TMZ [24], adjunct therapies that
can modulate EV release and result in anti-oncogenic signatures, irrespective of or in conjunction with
changes in EV numbers released, are of considerable interest. In the current study, both significant
reduction in EV release, as well as anti-oncogenic modulation of microRNA expression following
PAD isozyme-specific inhibitor treatment was observed in the two GBM cell lines, representative of a
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chemo-resistant (LN18) and chemo-sensitive (LN229) type [69]. A slight but significant increase in EV
modal size was furthermore observed in LN18 cells following PAD2 inhibitor treatment and may have
some relevance in cellular communication which will need further exploration, although aggregation of
EVs contributing to this shift in modal size identified by NTA analysis cannot be excluded at this stage.
Effects of the PAD isozyme-specific inhibitors on the modulation of microRNA EV-cargo highlight
approaches for targeted modulation of EV cargo to change GBM intra- and inter-tumour communication.
Both microRNAs and short non-coding RNAs have been identified in GBM EVs, with miR21 being
one of the highest expressed microRNAs [20]. Changes in miR21 have been shown to affect viability,
senescence and invasion in GBM [70–72], with miR21 silencing leading to decreased tumour size
and improved survival in GBM animal models [73]. Furthermore, exosomes engineered to suppress
miR21 were recently shown to reduce tumour volume in vivo in a rat GBM model [74]. Inhibition of
miR21 has also been shown to enhance chemo-sensitivity of TMZ-resistant GBM cells in vitro [75]. We
recently identified that miR21 was significantly reduced in LN18 and LN229 cells following pan-PAD
inhibitor treatment and identified in the current study that the PAD2 and PAD4 inhibitors were most
potent at reducing relative expression of miR21 in EV cargo of LN18 cells, while PAD3 inhibitor
showed strongest relative reduction in miR21 expression in LN229 cell-derived EVs, out of the three
PAD inhibitors tested. This also correlated with that PAD2 and PAD4 inhibitor most significantly
reduced cell invasion in LN18 cells, as assessed by Matrigel™ Invasion Chamber assay, while only
PAD3 inhibitor significantly affected cell invasion in LN229 cells.
In GBM-derived patient samples, miR126 has been found to be decreased and related to high
histopathological grades; while higher intra-tumoural miR126 levels are indicative of significantly
improved survival duration, compared to patients with lower miR126 levels [76]. Over-expression of
miR126 has been shown to suppress glioma cell proliferation and invasion in vitro [77]. Previously we
found that miR126 was significantly elevated in GBM cells and cell-derived EVs following pan-PAD
inhibitor treatment and have in the current study identified that in LN18 cell-derived EVs PAD2 and
PAD4 inhibitors were significantly effective in raising relative miR126 expression, while PAD3 specific
inhibitor was not effective in increasing relative miR126 expression in LN18 cell-derived EVs. In LN229
cell-derived EVs, only PAD3 inhibitor significantly increased relative levels of miR126 while PAD2 and
PAD4 inhibitors slightly (but significantly) decreased miR126; therefore, only PAD3 inhibitor achieved
the “protective” anti-oncogenic response by elevating relative levels of miR126 in LN229 cell-derived
EVs. Interestingly, cannabidiol, which is effective in GBM treatment [78,79] and was also recently
identified as an potent EV modulatory agent [37,38], has also been found to elevate miR126 and reduce
miR21 EV-cargos from LN18 and LN229 cells, possibly explaining some of its protective functions in
GBM [37].
miR210 has previously been identified as a major miR induced under hypoxia and has important
roles in mitochondrial metabolism, DNA damage response, cell proliferation and apoptosis [80]. MiR210
is furthermore implicated in the regulation of cell glycolytic activity, is linked to inflammation [81]
and is also involved in angiogenesis and vascular remodelling [82], including via EV-mediated
transport [83]. miR210 has been identified as a regulator of the hypoxia pathway [84,85] and belongs to
a group of hypoxia-mediated microRNAs, which are upregulated in glioma compared to normal brain
tissue [86] and upregulated in patient-derived glioblastoma spheroids upon hypoxia exposure [87].
Elevated plasma expression of miR210 has been found in GBM compared to low-grade astrocytoma
patients [88], as well as being elevated in serum and associated with tumour grade and poor patient
outcome [62]. miR210 is also elevated and associated with worse prognosis in higher grade GBM
tumours, compared to lower grade gliomas [61] and promotes hypoxic survival and chemoresistance
in GBM cells [89]. Furthermore, miR210 has recently been found to belong to miRs that encourage
radioresistance of GBM [63]. In the current study PAD2 and PAD4 inhibitors significantly reduced
relative miR210 levels in LN18 cell-derived EVs, while in LN229 cell-derived EVs only the PAD3
inhibitor significantly reduced relative miR210 levels.
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The observed decrease in pro-oncogenic miR21, hypoxia related and pro-oncogenic miR210 and
the increase in anti-oncogenic miR126 levels in GBM cell-derived EVs, caused by the different PAD
isozyme-specific inhibitors in the current study, indicates GBM cell type selective anti-GBM functions
of the different PAD isozyme-specific inhibitors. These observations highlight heterogeneity of PAD
isozyme expression in different GBM cell lines.
Modulation of proteins involved in cancer invasion and progression is of pivotal importance for
targeting cancer, including GBM. Targeted modulation of the invading GBM tumour edge, which can
act as a seed for recurrence [90], is therefore of considerable importance. New strategies for regulation
of invasion-proteins including via inhibition of post-translational deimination, which may facilitate,
for example, actin assembly and proteins involved in filopodia formation, as well as targeting proteins
linked to stem-ness in the tumour periphery, promoting tumour invasion and rapid tumour progression,
may therefore be of interest.
Previously we established that pan-PAD inhibitor Cl-amidine modulated cancer promoting
proteins, including in GBM [9,33]. Prohibitin is a multifaceted protein involved in cell survival and
apoptosis and a key mitochondrial house-keeping protein [41,44]. We had previously identified that
pan-PAD inhibitor Cl-amidine reduced PHB expression somewhat following 1 h treatment, in addition
to affecting post-translational deimination, in the two GBM cell lines under study [9], although such
effects were more pronounced in the LN18 cell line [9]. In the current study, PAD isozyme-specific
inhibition highlighted differences between the two GBM cell lines and PAD isozyme-specificity on
regulation of PHB protein levels, following 1 h treatment. In LN18 cells, PAD3 inhibitor led to a
significant reduction in PHB levels, correlating with previous findings that Cl-amidine (pan-PAD
inhibitor with most specificity for PAD3) affected PHB levels in this GBM cell line [9]. Both PAD2
and PAD4 inhibitor less effectively modified PHB levels in LN18 cells, with PAD2 inhibitor somewhat
more effective in lowering PHB levels (albeit not significantly) than PAD4 inhibitor, following 1 h
treatment. In LN229 cells PHB reduction was more pronounced following 1 h treatment with PAD2
and PAD3 inhibitors, although not significant and overall less than for LN18 cells. This correlates
with previous findings showing non-significant changes in PHB levels in LN229 cells using pan-PAD
inhibitor Cl-amidine for the same time duration [9].
STIM-1 was previously identified to be a deiminated protein candidate in GBM cells by our
group [9], and folding dynamics of STIM-1 have been discussed with respect to adaption to differential
roles in Ca2+ homeostasis and signalling [45]. Roles for STIM-1 in Ca2+ entry mechanisms have
been highlighted in a range of pathophysiological processes including infection and cancer [91].
As STIM-1 plays roles in Ca2+ regulation, it also has effects on EV release, which is in part a Ca2+
mediated mechanism and furthermore may impact mitochondrial function. Reduction in STIM-1
protein expression observed in the current study, following PAD isozyme-specific inhibitor treatment,
correlates with a significant reduction observed in EV release. STIM-1 activity has indeed been shown to
be essential for GBM invasion [46]. In studies on GBM human U251 and rat C6 cells, STIM-1 knockdown
has been shown to reduce Ca2+ influx and to inhibit tumour cell proliferation and induce apoptosis [92].
Higher STIM-1 expression is correlated with migration, tumour size and clinical outcome in cervical
cancer [93] and such correlation with tumour size is also seen in breast cancer [94]. Furthermore,
STIM-1 enhances cell migration and promotes metastasis of cancer cells [93,95]. The findings reported
in the current study, showing reduction of STIM-1 protein following PAD isozyme-specific inhibitor
treatment, align with these previous studies as the PAD inhibitors lead to reduced STIM-1 protein and
also to reduced cell migration, as assessed by reduced invasion observed for GBM cells following
PAD inhibitor treatment. In LN18 cells, PAD4 inhibitor was most effective at lowering STIM-1 levels,
while in LN229 cells PAD3 inhibitor was significantly and most effective, with PAD2 and PAD4 inhibitor
leading to some (but not significant) reduction of STIM-1.
Moesin is an ezrin-radixin-moesin (ERM) family member and involved in the regulation of cell
adhesion, polarity and migration [96]. Moesin connects the actin cytoskeleton to transmembrane
receptors, and its upregulation is correlated with increased cell invasion and migration in GBM [49].
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Moesin has been associated with filopodia formation, which are dynamic actin-rich membrane
protrusions important for cell adhesion, membrane trafficking (including EV internalisation) [48]
and therefore also of importance in cancer cell adhesion and invasion [97–99]. The correlation of
moesin overexpression with higher grade GBM has also been related to its ability to increase stem cell
neurosphere formation [50,100], which may furthermore promote stem-ness (which correlates with
aggressiveness and chemo-resistance) in GBM. Increased moesin expression is related to invasion
and metastasis and is also correlated to a progressive pathological state of pancreatic [101] and breast
cancer [102]. In the current study PAD isozyme-specific inhibition resulted in some reduced moesin
levels, which differed between the two GBM cell lines and PAD isozyme-specific inhibitor treatment.
Moesin was not reduced by any PAD-isozyme inhibitor treatment in the LN18 cells, which overall have
been reported to also be more chemo-resistant [69], while in LN229 cells PAD2 and PAD3 inhibitor
lowered moesin levels following 1 h treatment.
It must be noted that the current study assessed changes in total protein levels only, following 1 h
PAD inhibitor treatment of the three proteins under study, while PAD inhibition may also affect changes
in post-translational deimination of the proteins, affecting protein–protein interactions, and this will
need further detailed evaluation, including at longer time-points. The results of the invasion cell
assay were assessed after a longer time-point, following 16 h, and do correlate with the anti-oncogenic
signatures observed following 1 h PAD isozyme-specific treatment. Overall, more target proteins
were found to be deiminated in LN18 cells compared to LN229 cells, and this also correlated with
more significant effects of PAD inhibition on invasion in LN18 cells. We verified that all three proteins
under study are post-translationally deiminated in both cell lines (Supplementary Figure S1B) while
FoldIndex© analysis [103] furthermore shows that both STIM-1 and moesin are highly unfolded proteins
(Supplementary Table S1), which makes them susceptible for post-translational deimination [40,104,105].
While PHB does not show any unfolded regions, a high number of arginines are present, and these
pose as sites for citrullination/deimination (Supplementary Table S1). Furthermore, we previously
showed that PHB deimination was reduced in GBM cells following 1 h pan-PAD inhibition [9]. Further
in-depth investigation into roles for the most critical arg/cit conversions in the context of PAD-inhibitor
treatment and PAD isozyme-specific preferences for deimination of target proteins could for example
be explored using site-directed mutagenesis in selected proteins.
Our findings indicate differences in function of PAD isozymes 2, 3 and 4 in the two GBM cell
lines, also differently affecting pro-oncogenic protein expression. PAD isozyme-specific inhibitor
treatment in the two GBM cell lines reflects to some extent the finding that PAD2 and PAD4 are higher
expressed in LN18 cells compared to PAD3, while PAD3 is higher expressed in LN229 cells compared
to PAD2 and PAD4 [9] (Supplementary Figure S1A). This is in accordance with the PAD3 inhibitor
being most effective at reducing EV release from LN229 cells and most effectively reducing STIM-1
protein levels in LN229 cells. Furthermore, PAD3 inhibitor most effectively modulated the three
microRNAs under study to an anti-oncogenic signature in the LN229 cell-derived EVs. A similar
trend was observed for LN18 cells, where PAD2 and PAD4 inhibitors most effectively reduced EV
release (while PAD3 inhibitor had no significant effect) and also significantly modulated the three
microRNAs to an anti-oncogenic signature in the cell-derived EVs. The PAD-inhibitor mediated effects
on reducing protein levels of STIM-1, moesin and PHB, all pro-oncogenic proteins, was less prominently
pronounced, although overall a trend for PAD2 and PAD4 inhibitors was observed in LN18 and for
the PAD3 inhibitor in LN229 cells. The PAD isozyme-specific inhibitors affected cell invasiveness
differently in the two GBM cell lines and were overall more effective in reducing invasiveness in
LN18 cells, with PAD2 inhibitor being most effective but overall all three PAD inhibitors showing
significantly reduced invasion of LN18 cells, while in LN229 cells only PAD3 inhibitor significantly
reduced invasion following 16 h treatment. Furthermore, relative expression of miR21, involved in cell
invasion, was most significantly reduced by PAD2 and PAD4 inhibitors in EV cargo from LN18 cells and
by the PAD3 inhibitor in EV cargo from LN229 cells. Overall, this indicates isozyme-specific selection
of target proteins and miRs involved in invasion, also as PAD isozyme expression significantly differed
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between the two cell lines (Supplementary Figure S1A; [9]). In both cell lines, the PAD inhibitors
seemed to promote invasiveness independently of proliferation. This furthermore highlights current
challenges in the treatment of GBM, which are known to be a highly heterogeneous group of tumours.
In both GBM cell lines under study, enrichment of deiminated proteins in a number of KEGG
pathways was identified under normal culture conditions. Some pathways were common to
both cell lines (including glycolysis/gluconeogenesis, ribosome, splicosome, oestrogen signalling
pathway, carbon metabolism, bacterial infection, antigen processing and presentation, Huntington’s
disease), while some KEGG pathways differed between the two cell lines. Interestingly, deiminated
KEGG pathways for HIF-1 were identified in LN18 cells only, but not in LN229 cells, under normal
conditions, and this may be indicative of some differences in hypoxia regulation via post-translational
deimination. HIF-1 expression plays a major role in GBM development and progression, participating
in glucose uptake, cancer proliferation, cell mobility, cancer stem cell metabolic reprogramming and
chemo-resistance [106–109]. Inhibition of HIF-1 has been shown to induce cell death of GBM [110],
and HIF-1 over-expression and silencing studies have furthermore shown regulation of specific miRNAs,
including miR210, to be HIF-1 dependent [89]. To what extent deimination of these pathways plays
roles in the regulation of hypoxia resistance and chemo-resistance remains to be further investigated.
Interestingly, deimination of HIF-1 related KEGG pathways has recently been described in animal
models of cancer resistance and hypoxia tolerance [56,57]. Furthermore, KEGG pathways for thyroid
hormone synthesis were identified to be enriched for deiminated proteins in LN18 cells only. Thyroid
hormone synthesis has been suggested as one of the pathogenic factors of GBM, with implications
in formation and course of GBM pathogenesis [111,112]. LN18 cells also showed enrichment for
deiminated proteins in KEGG pathways for Epstein–Barr virus infection (EBV). The relationship
between EBV and GBM still remains to be fully understood [113] and has been recognized to be
associated with worse patient prognosis [114]. In LN18 cells, deiminated proteins were enriched
for the necroptosis pathway, which has been highlighted as a novel therapeutic target for GBM,
as necrosis seems to be related to GBM proliferation, angiogenesis and invasion [115]. As necroptosis
is a pathological and radiological hallmark of GBM [116], it has been proposed that modulating
necroptosis in GBM could circumvent apoptosis resistance, which is common in GBM [115,117,118].
Therefore, regulation via post-translational deimination of these pathways, which could be targeted via
selective PAD-inhibitors, may be of some interest. KEGG pathways for phagosome were also found to
be enriched in protein deimination in LN18 cells. Phagosome KEGG pathways have been identified to
be associated with TMZ resistance in GBM at the proteomic level [119] and related to the progression
of glioma into glioblastoma by gene expression profiling [120]. Therefore, regulation via deimination
may also be of considerable interest, particularly as this pathway was detected in LN18 cells, which are
reported to be the more chemo-resistant of the two GBM cell lines [69]. While KEGG pathways for
glycolysis, which is of high relevance for GBM [121], were identified to be deiminated in both GBM cell
lines, the pentose phosphate pathway (PPP) was identified as a deimination KEGG pathway in LN18
cells only and the KEGG pathway for pyruvate metabolism in LN229 only. Both are related to glycolysis,
with the PPP associated with cell migration and glial tumour aggressiveness [122,123]. Pyruvate
plays a key role in GBM metabolic reprogramming [124] and modulation of the pyruvate pathway
induces alterations of metabolic and stress-related pathways in GBM [121] also with putative roles in
hypoxia-dependent resistance of GBM [110]. While carbon metabolism KEGG pathway was identified
for deiminated proteins in both GBM cell lines, KEGG pathway for central carbon metabolism in cancer
was identified in LN18 cells only. Carbon metabolism is related to metabolic adaption and growth
in GBM [125,126], including in TMZ resistance [127] and in the control of glioma cell transformation
to a higher aggressive stage [109]. Roles for post-translational deimination in such metabolic control
have not been investigated and may be of relevance as this pathway was prominent for deimination in
LN18 cells, which present a more aggressive and chemo-resistant form than LN229 [69]. Interestingly,
enrichment of deiminated proteins in carbon metabolism KEGG pathway has also been recently
recognized in whales [57], which are hypoxia tolerant and long-lived mammals displaying cancer
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resistance [128]. Only LN229 cells showed enrichment of deiminated proteins in IL-17 KEGG pathway,
and this was not found in LN18 cells. Regulation of IL-17 via post-translational deimination may be of
interest for recent IL-17 inhibitor treatment approaches, which were shown to decrease GBM tumour
hypoxia, angiogenesis and tumour growth in animal models [129]. Furthermore, KEGG pathways for
bacterial infection were identified to be deiminated in both GBM cell lines (pathogenic E. coli) but more
prominently for LN18 cells (E. coli, salmonella and legionellosis). This may be of relevance for success of
using bacterial carriers for glioblastoma therapy [130] as well as for management of bacterial infection
following GBM surgery and treatment [131–134]. Indeed, critical roles for PADs, including pan-PAD
and PAD-isozyme specific regulation of bacterial membrane vesicle release, critical for host-pathogen
interactions, and in bacterial drug resistance, have recently been described [135]. Furthermore, the
modulation of the host’s immune proteins via post-translational deimination by bacterial arginine
deiminases is also a recognized mechanism for immune evasion [136].
The differences identified in the current study in deiminated KEGG pathways between the two
GBM cell lines may indicate selective differences in the preference of target proteins for deimination
by the different PAD-isozymes, particularly as in LN18 cells PAD2 and PAD4 isozymes are more
prominently expressed while PAD3 is found at higher levels compared to PAD2 and PAD4 in LN229
cells [9].
In summary, our findings indicate PAD isozyme-specific regulation in the pro-oncogenic
communication in GBM and highlight the potential of using PAD-isozyme specific inhibition for
tailored treatment in GBM subtypes.
4. Materials and Methods
4.1. GBM Cell Cultures and PAD-Inhibitor Treatment
LN18 (ATCC® CRL-2610™, grade IV glioblastoma derived from a male patient with a right
temporal lobe glioma) and LN229 (ATCC® CRL-2611™, glioblastoma derived from a female patient
with right frontal parietal-occipital glioblastoma) were cultured according to ATCC’s recommendations,
to 80% confluence in 75 cm2 flasks in complete Dulbecco’s Modified Eagle’s Medium (DMEM), with 10%
foetal bovine serum (FBS) at 37 ◦C/5% CO2. Cells were split every 3–5 days, depending on confluence.
The cell lines were chosen as an example of a chemo-resistant (LN18) and chemo-sensitive (LN229)
GBM cell line respectively, according to previously published literature [69]. GBM cells were grown
to 80% confluency before 1 h treatment with PAD2 (AMF30a, 5 µM; [137]), PAD3 (Cl-4 amidine,
10 µM; [138]) and PAD4 (GSK199, 10 µM; [139]) inhibitors, respectively, based on cell viability tests
(see Section 4.2 and Supplementary Figure S2) and previously published literature [39,135,137–139].
The PAD inhibitors were dissolved in 0.001% DMSO), and DMSO (0.001%) treated cells were used as
controls. For effects on EV release, protein and microRNA expression, cells were treated for 1 h with
the PAD inhibitors, while for cell proliferation and invasion assays, treatment time was 16 h. For EV
isolation, before application of the PAD inhibitors, the serum-containing medium was removed to
avoid contamination of EVs from the FBS; the cells were washed in DPBS, and thereafter, serum-free
medium containing the respective PAD-inhibitors (or corresponding DMSO control) were added for 1 h.
Following 1 h incubation, the medium was removed from all treatments for EV isolation (Section 4.4),
and the cells were trypsinised for subsequent protein extraction and western blotting (Section 4.7).
4.2. Cell Viability Assays following PAD Inhibitor Treatment
Cell viability of LN18 and LN229 GBM cells was assessed after 1 h incubation with PAD2 (AMF30a,
5 µM), PAD3 (Cl4-amidine, 10 µM) and PAD4 (GSK199, 10 µM) inhibitors, respectively, compared to
DMSO control-treated cells (Supplementary Figure S2). Glioblastoma cell lines LN18 and LN229 were
seeded at a density of 1 × 104 on to a 96 well plate (Nunc, Roskilde, Denmark) for 2–3 days. Cells were
treated with either medium only, DMSO, PAD2 (AMF30a; 5 µM), PAD3 (Cl4-amidine; 5, 10, 50, 100 µM)
and PAD4 (GSK199; 10 µM) inhibitors respectively, for 1 h at 37 ◦C, 5% CO2. PrestoBlue Cell Viability
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Reagent (ThermoFisher Scientific, Dartford U.K.) was added (1:10 dilution) to each well and incubated
for 10 min at 37 ◦C, according to the manufacturer’s instructions (ThermoFisher). Fluorescence was
measured using CLARIOstar plate reader (BMG Labtech, Aylesbury, Bucks, U.K.) at 545-20/600-40 nm.
4.3. Modulation of EV Release Using PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors Following
1 h Treatment
The effect of PAD2 (AMF30a; 5 µM), PAD3 (Cl4-amidine; 10 µM) and PAD4 (GSK199; 10 µM)
specific inhibitors on EV release from GBM LN18 and LN229 cells was assessed following 1 h
incubation time with the PAD2, 3 or 4 isozyme-specific inhibitors, respectively. LN18 and LN229
cells were cultured and maintaied in T75 flasks, in triplicates, in the presence of culture medium
(pre-warmed DMEM, supplemented with 10% FBS; Sigma-Aldrich, Gillingham, U.K.), according
to ATCC’s recommendations. LN18 and LN229 cells were grown to 80% confluency per T75 flask,
whereafter the cells were split in culture medium (10 mL per T75 flask of pre-warmed DMEM,
supplemented with 10% FBS; Sigma-Aldrich, U.K.) in preparation for each experiment, which then
was carried out 2–3 days following splitting, and upon the cells in the flasks reaching 70% to 80%
confluency. For EV isolation, treatment with the PAD isozyme-specific inhibitors and 0.001% DMSO,
respectively, was carried out in biological triplicate per treatment as follows: Before PAD inhibitor (or
DMSO control) treatment, the serum-containing medium was removed from the T75 flasks containing
the cell preparations, to avoid contamination of EVs from the FBS in the medium, and the cells were
washed three times with pre-warmed Dulbecco’s PBS (DPBS). Thereafter, fresh pre-warmed serum-
and EV-free DMEM containing either the PAD inhibitors (dissolved in 0.001% DMSO, in 5 mL medium
per T75 flask) or DMSO (0.001%, in 5 mL medium per T75 flask) were added. The cells were incubated
for 1 h in the presence of the PAD-inhibitors (and DMSO control) at 37 ◦C/5% CO2. Following 1 h
incubation time, the EV-containing media (5 mL per T75 flask) were collected from the flasks. Cell
debris was removed by centrifugation at 200 g for 10 min, and thereafter, EVs were isolated from the
remaining supernatant as described in Section 4.4. The PAD2-inhibitor and PAD4-inhibitor treatments
with a corresponding DMSO control were run together; PAD3-inhibitor treatment and a corresponding
DMSO control treatment were run together, as reflected in the histograms in Figures 1 and 3.
4.4. EV Isolation and Quantification by Nanoparticle Tracking Analysis
EV isolation was carried out according to established protocols [9,36,38] and according to the
recommendations of the International Society of Extracellular Vesicle Research (ISEV) [140]. Differential
centrifugation was carried out on the cell culture supernatants (5 mL collected from each flask) as
follows: First the supernatants were centrifuged at 4000 g for 30 min at 4 ◦C to remove cell debris,
followed by centrifugation of the collected supernatant for 1 h/4 ◦C at 100,000 g. The supernatant was
discarded and the isolated EV pellets were resuspended and washed in ice-cold DPBS, centrifuged
again at 100,000 g for 1 h/4 ◦C, and thereafter, the final EV enriched pellet was resuspended in 100 µL
sterile EV-free PBS. Nanoparticle tracking analysis (NTA) was carried out using the NS300 Nanosight
(Malvern Panalytical Ltd., Malvern, U.K.), equipped with a sCMOS camera and a 405 nm diode laser,
to enumerate the EVs. Samples were diluted 1:100 in sterile-filtered EV-free DPBS, and the number of
particles in the field of view was maintained in the rage of 30–50 with a minimum concentration of
samples at 5 × 107 particles/mL. Camera settings were according to the manufacturer’s instructions
(Malvern Panalytical Ltd.), recording five 60 s videos per sample and averaging the obtained replicate
histograms. Each experiment was repeated in three biological replicates.
4.5. EV Characterisation by Transmission Electron Microscopy
Isolated EVs from LN18 and LN220 cells were resuspended in 100 mM sodium cacodylate buffer
(pH 7.4). A drop (~3–5 µL) of the suspension was placed on to a grid with carbon support film,
which had previously been glow discharged. When the suspension had partly dried, the grid was
placed on a drop of solution of 2.5% glutaraldehyde in 100 mM sodium cacodylate buffer (pH 7.4) for
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1 min and washed afterwards by touching it to the surface of three drops of distilled water. Excess
water was removed by touching the grid to a filter paper. A small drop of stain (2% aqueous Uranyl
Acetate; Sigma-Aldrich) was then applied to the grid. After 1 min, the excess stain was removed
by touching the edge to a filter paper. The grid was dried at room temperature and thereafter the
samples were viewed in TEM. Imaging was performed using a JEOL JEM 1400 transmission electron
microscope (JEOL, Tokyo, Japan) operated at 80 kV at a magnification of 30,000 to 60,000. Digital
images were recorded using an AMT XR60 CCD camera (Deben, Bury Saint Edmunds, U.K.).
4.6. Analysis of microRNAs miR21, miR126 and miR210 in GBM Cell EV-Cargo Following 1h PAD
Inhibitor Treatment
For assessment of microRNA cargo in the GBM-derived EVs, LN18 and LN229 cells were cultured
to 80% confluency in T75 flasks in DMEM supplemented with 10% FBS as before. The cells were
washed with EV-free DPBS, and thereafter, fresh EV and serum-free medium was added, containing
the PAD-isozyme specific inhibitors (same concentrations as before), and 0.001% DMSO for control
treatment. After 1 h incubation time, the cell medium was collected for EV isolation. EVs were isolated
as described above and thereafter processed for RNA isolation, cDNA translation and assessment for the
relative expression of miR21, miR126 and miR210. RNA was extracted from treated and control-treated
cells using Trizol (Sigma, U.K.), and RNA concentration and purity was measured using the NanoDrop
Spectrophotometer (ThermoFisher Scientific, Dartford, U.K.) at 260 nm and 280 nm absorbance. RNA
was reverse transcribed to cDNA using the qScript microRNA cDNA Synthesis Kit (Quantabio, Beverly,
MA, USA) according to the manufacturer’s protocol. The resulting cDNA was used to assess the
expression of microRNAs miR21, the main microRNA associated with pro-oncogenic function, miR126,
associated with protective function in GBM, and miR210, associated with hypoxia and pro-oncogenic
environment in GBM. U6-snRNA and hsa-let-7a-5p were used as a reference RNA for normalization of
miR expression levels. The PerfeCTa SYBR® Green SuperMix (Quantabio, USA) was used together
with MystiCq microRNA qPCR primers for miR21 (hsa-miR-21-5p), mir126 (hsa-miR-126-5p) and
miR210 (hsa-miR-210-5p), which were obtained from Sigma (U.K.). The sequences for U6-snRNA
primers were U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and hsa-let-7a-5p forward
5′-CCGAGCTGAGGTAGTAGGTTGTATA-3′ reverse 5′-CGCTTCACGAATTTGCGTGTCAT-3′ for
both. The thermocycling conditions were as follows: denaturation at 95 ◦C/2 min, followed by 40 cycles
at 95 ◦C/5 s and 60 ◦C/15 s and extension at 72◦ C/15 s. The miR21, miR126 and miR210 expression
levels were normalized to that of U6 using the ∆∆CT method according to Livak and Schmittgen [141].
The experiments were carried out in 3 biological and 3 technical repeats.
4.7. Western Blotting Analysis
Total protein was extracted from treated and control-treated LN18 and LN229 cells, in the presence
of RIPA+ buffer (Sigma, U.K.) containing 10% protease inhibitor complex (Sigma), pipetting gently
with regular intervals while shaking the cell preparation on ice for 2 h. Thereafter, the cell preparations
were centrifuged at 16,000 g (4 ◦C/20 min) and the supernatant containing the extracted proteins
collected. The protein extracts were either used immediately for immunoprecipitation and proteomic
analysis or re-constituted in 2 x Laemmli sample buffer for western blotting. Protein extracts from
LN18 and LN229 cells, in 2 x Laemmli sample buffer containing 5% β-mercaptoethanol, were boiled
for 5 min at 100 ◦C before separation by SDS-PAGE, using 4% to 20% Mini-Protean TGX protein gels
(BioRad, Deeside, U.K.), followed by semi-dry western blotting analysis. Even transfer to nitrocellulose
membranes (0.45 µm, BioRad) was assessed using Ponceau S staining (Sigma). The membranes were
blocked for 1 h at room temperature (RT) in 5% BSA (Sigma) in Tris buffered saline (TBS) with 0.1%
Tween20 (TBS-T), followed by overnight incubation at 4 ◦C with the following primary antibodies for
the cell lysates (used 1/1000 in TBS-T): anti-PAD2 (ab50257, Abcam), anti-PAD3 (ab50246), anti-PAD4
(ab50332), anti-prohibitin (ab75771), anti-STIM-1 (ab57834), anti-moesin (ab52490). For characterization
of EVs, isolated EVs were assessed by WB using the EV-specific markers CD63 (ab68418; 1/1000 in
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TBS-T) and Flot-1 (ab41927; 1/2000 in TBS-T). Following primary antibody incubation, membranes
were washed in TBS-T, incubated for 1 h at RT with the corresponding HRP-conjugated secondary
antibodies (anti-rabbit IgG, BioRad, U.K.), followed by TBS-T washes and visualisation using enhanced
chemilumnicence (ECL; Amersham, U.K.) and the UVP BioDoc-ITTM System (Thermo Fischer Scientific,
Hemel Hempstead, U.K.) HRP-conjugated anti-β-actin antibody (ab20272, Abcam, 1/5000 in TBS-T)
was used as an internal loading control and for assessment for the purity of EV isolation (confirmed
by absence of β-actin). Densitometry analysis of PHB, STIM-1 or moesin protein levels relative to
the internal actin control was carried out, for assessment of changes in total protein levels between
PAD-inhibitor treated and control-DMSO treated cells, using ImageJ [142].
4.8. Cancer Cell Invasion Assay
Cell invasion assay was performed as previously described in detail [143]. Briefly, 5 × 105
cells (treated with the PAD isozyme-specific inhibitors or DMSO control as before) were plated on
Matrigel-coated transwell filters (Corning™ BioCoat™ Matrigel™ Invasion Chamber with Corning™
Matrigel Matrix; BD Biosciences, Wokingham, Berkshire, U.K.) in a chemotactic gradient of 1:10%
FBS. After 16 h incubation, the total number of invaded cells was determined by MTT assay (Abcam,
Cambridge, U.K.) and further confirmed by crystal violet assay (Abcam, U.K.). In parallel, the same
number of cells was plated and incubated for 16 h to determine the effect of the PAD isozyme-specific
inhibitors on cell proliferation by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
assay. Absorbance was measured using CLARIOstar plate reader (BMG Labtech, Aylesbury, U.K.) at
540–590 nm and normalised according to the control. The experiments were performed in 3 biological
and 3 technical repeats.
4.9. Assessment of KEGG Pathways for Deiminated Proteins in LN18 and LN229 GBM Cells under Standard
Culture Conditions
Protein extracts from LN18 and LN229, obtained by protein extraction using RIPA+ buffer,
were added to mini-prep sepharose columns in the presence of the pan-deimination F95 antibody
(MABN328, Merck, Nottingham, U.K.) for immunoprecipitation of total deiminated proteins using the
Catch and Release® v2.0 Immunoprecipitation Kit according to the manufacturer’s instructions (Merck,
Nottingham, U.K.) F95 enrichment was carried out overnight at 4 ◦C on a rotating platform. and the
F95 bound proteins were thereafter eluted using denaturing elution buffer (Merck), according to the
manufacturer’s instructions. F95-enriched eluates from both GBM cell lines were thereafter analysed
by liquid chromatography with tandem mass spectrometry (LC-MS/MS; Cambridge Proteomics,
Cambridge, U.K.). For LC-MS/MS, the F95 enriched eluates were run 0.5 cm into a 15% TGX gel
(BioRad, U.K.) and each cut out as one band. The 1D gel bands were transferred into a 96-well PCR
plate. The bands were cut into 1 mm2 pieces, destained, reduced (DTT) and alkylated (iodoacetamide)
and subjected to enzymatic digestion with trypsin overnight at 37 ◦C. After digestion, the supernatant
was pipetted into a sample vial and loaded onto an autosampler for automated LC-MS/MS analysis.
All LC-MS/MS experiments were performed using a Dionex Ultimate 3000 RSLC nanoUPLC (Thermo
Fisher Scientific Inc, Waltham, MA, USA) system and a QExactive Orbitrap mass spectrometer (Thermo
Fisher Scientific Inc, Waltham, MA, USA). Separation of peptides was performed by reverse-phase
chromatography at a flow rate of 300 nL/min and a Thermo Scientific reverse-phase nano Easy-spray
column (Thermo Scientific PepMap C18, 2 µm particle size, 100A pore size, 75 µm i.d. × 50 cm length).
Peptides were loaded onto a pre-column (Thermo Scientific PepMap 100 C18, 5 µm particle size, 100A
pore size, 300 µm i.d. × 5 mm length) from the Ultimate 3000 autosampler with 0.1% formic acid for 3
min at a flow rate of 10 µL/min. After this period, the column valve was switched to allow elution of
peptides from the pre-column onto the analytical column. Solvent A was water +0.1% formic acid and
solvent B was 80% acetonitrile, 20% water +0.1% formic acid. The linear gradient employed was 2% to
40% B in 30 min. The LC eluant was sprayed into the mass spectrometer by means of an Easy-Spray
source (Thermo Fisher Scientific Inc.). All m/z values of eluting ions were measured in an Orbitrap
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mass analyser, set at a resolution of 70,000 and was scanned between m/z 380–1500. Data dependent
scans (Top 20) were employed to automatically isolate and generate fragment ions by higher energy
collisional dissociation (HCD, NCE:25%) in the HCD collision cell and measurement of the resulting
fragment ions was performed in the Orbitrap analyser, set at a resolution of 17,500. Singly charged ions
and ions with unassigned charge states were excluded from being selected for MS/MS, and a dynamic
exclusion window of 20 s was employed. Post-run, the data was processed using Protein Discoverer
(version 2.1., Thermo Scientific). Briefly, all MS/MS data were converted to mgf files, and the files
were then submitted to the Mascot search algorithm (Matrix Science, London UK). The hit search was
carried out against the UniProt Homo sapiens database (Homo_sapiens_20180131; 71,785 sequences;
24,195,788 residues; in-house Cambridge Proteomics, U.K.) and a common contaminant sequences
database (117 sequences; 38,809 residues; in-house Cambridge Proteomics, U.K.). The peptide and
fragment mass tolerances were set to 20 ppm and 0.1 Da, respectively. A significance threshold value
of p < 0.05 and a peptide cut-off score of 20 were also applied. For the identification of putative
protein–protein interaction networks for deiminated proteins identified in LN18 and LN229 GBM cells,
STRING analysis (Search Tool for the Retrieval of Interacting Genes/Proteins; https://string-db.org/)
was used. Protein networks were built by using the function of “search multiple proteins” in STRING,
choosing “Homo sapiens” as the species database and applying basic settings and medium confidence,
with colour lines between nodes indicating evidence-based interactions for network edges as follows:
known interactions (based on curated databases, experimentally determined), predicted interactions
(based on gene neighbourhood, gene fusion, gene co-occurrence) or via text mining, co-expression or
protein homology.
Human prohibitin (AAB21614.1), moesin (NP_002435.1) and STIM-1 (AAH21300.1) protein
sequences were further analysed for putative disordered regions using FoldIndex© analysis (https:
//fold.weizmann.ac.il/fldbin/findex) [103,144].
4.10. Statistical Analysis
The graphs were prepared, and statistical analysis was performed using GraphPad Prism version
7 (GraphPad Software, San Diego, CA, USA). One-way ANOVA was performed followed by Tukey’s
post-hoc analysis. Experiments were repeated in three biological triplicates for EV analysis and
western blotting, and in three biological and three technical triplicates for microRNA analysis and
cell invasion assays. NTA curves were generated by the NanoSight 3.0 software (Malvern, U.K.)
with the black line representing the mean of the 5 repetitive readings per individual sample (each
treatment group was repeated in 3 biological replicates) and the red line representing standard error
(+/−). Histograms represent mean of data, and standard deviation (SD) is indicated by the error bars.
Significant differences were considered as p ≤ 0.05.
5. Conclusions
In summary, the findings of the current study highlight effects of PAD isozyme-specific regulation
of EV release, modulation to anti-oncogenic microRNA signatures of EVs and effects on GBM cell
invasion, including via effects on proteins involved in mitochondrial metabolism and invasion.
Furthermore, our findings suggest differences in the regulation of KEGG pathways and protein–protein
interaction networks, underlying pathogenesis of GBM tumours, via post-translational deimination.
The findings presented here highlight recently identified roles for PADs in GBM, the need to assess
PAD isozyme-specific processes in the heterogeneity of GBM and the potential for tailored treatment of
GBM subtypes, using targeted PAD isozyme-specific inhibitors.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/4/1495/
s1. Supplementary Figure S1. PAD isozyme detection and deimination of PHB, STIM-1 and moesin in LN18 and
LN229 GBM cells. A. PAD2 and PAD4 protein detection is relatively higher in LN18, compared to LN229 cells (by
63% and 90%, respectively), while PAD3 protein detection is relatively higher in LN229, compared to LN18 cells (by
36%). B. PHB, STIM-1 and moesin are post-translationally deiminated in both LN18 and LN229 cells as assessed by
blotting the F95-enriched proteins (IP:F95) from both cell lines against the three antibodies. Relative densitometry
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compared to internal actin-control is represented by “R”. Supplementary Figure S2. GBM cell viability following
1 h PAD2, PAD3 and PAD4 isozyme-specific inhibitor treatment. LN18 and LN229 cell viability was assessed
by PrestoBlue assay following 1 h incubation with the PAD2 (AMF30a; 5 µM), PAD3 (Cl4-amidine; 5, 10, 50 and
100 µM) and PAD4 (GSK199; 10 µM) isozyme-specific inhibitors. Supplementary Figure S3. Protein–protein
interaction network analysis of deiminated proteins in LN18 cells. KEGG pathways identified for F95 enriched
proteins in LN18 cells are highlighted for: (A) immune responses, (B) metabolic pathways, (C) cancer-related
pathways. Supplementary Figure S4. Protein–protein network analysis of deiminated proteins in LN229 cells.
KEGG pathways identified for F95 enriched proteins in LN229 cells are highlighted for: (A) immune responses,
(B) metabolic pathways, (C) cancer-related pathways. Supplementary Table S1. FoldIndex© analysis of prohibitin,
moesin and STIM-1. All three proteins were verified to be deiminated in LN18 and LN229 GBM cells under
normal culture conditions. The number of disordered regions, residue length of the longest disordered region,
total number of disordered residues, as well as number of arginines present in the total number of residues for the
individual proteins is shown. Supplementary Table S2. LC-MS/MS analysis of F95 enriched proteins in LN18
cells. The full list of protein hits identified following protein immunoprecipitation using the pan-deimination
F95 antibody in LN18 GBM cells is presented. Supplementary Table S3. LC-MS/MS analysis of F95 enriched
proteins in LN229 cells. The full list of protein hits identified following protein immunoprecipitation using the
pan-deimination F95 antibody in LN229 GBM cells is presented.
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GBM Glioblastoma multiforme
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PHB Prohibitin
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
TBS Tris buffered saline
TEM Transmission electron microscopy
STIM-1 Stromal interaction molecule 1
WB Western blotting
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